# Nephrotic Syndrome Biopsy Indications

Kidney biopsy is usually required for unexplained adult nephrotic syndrome, but selected patients with PLA2R-positive membranous nephropathy may avoid it. In children, steroid response, age, atypical features, genetic risk, and failure to remit determine whether biopsy changes management.

**Clinical question:** When should adults and children with nephrotic syndrome undergo native kidney biopsy?

Updated: 2026-09-15T21:50:33.648356+00:00

## What matters in practice
- In adults with nephrotic syndrome and no evident cause after initial evaluation, obtain a native kidney biopsy because pathology commonly directs disease-specific treatment. [13][14]
- A new adult presentation with serum PLA2R antibodies can establish primary membranous nephropathy without biopsy in selected cases; PLA2R-negative nephrotic syndrome still requires tissue diagnosis. [14]
- Do not routinely biopsy a young child with typical idiopathic nephrotic syndrome before initial glucocorticoid treatment; failure to achieve remission by 6 weeks defines steroid resistance and should prompt biopsy and genetic evaluation. [1][16][19]
- Biopsy at initial presentation is favored in children older than 12 years because focal segmental glomerulosclerosis and other glomerular diseases become more frequent. [17]
- During pregnancy, biopsy is justified when de novo nephrotic syndrome, abrupt kidney-function decline, or suspected glomerulonephritis will change management; complication rates are higher antepartum than postpartum. [9][10]

## Biopsy most adults with unexplained nephrotic syndrome

Use serology to identify the narrow group in whom tissue can reasonably be deferred.

Obtain a native kidney biopsy in an adult with nephrotic syndrome when the cause is not evident from the initial evaluation. This remains the default diagnostic pathway because adult nephrotic syndrome includes membranous nephropathy, focal segmental glomerulosclerosis (FSGS), minimal change disease, amyloidosis, fibrillary or immunotactoid glomerulopathy, and Fabry disease, for which histology has distinct therapeutic and prognostic consequences. [13][14]

Order serum anti-phospholipase A2 receptor antibody (PLA2R-Ab) testing early in a new adult nephrotic presentation. A positive PLA2R-Ab result is sufficiently specific for primary membranous nephropathy that histologic confirmation is not necessary in selected new-onset cases; absence of PLA2R antibodies removes that exception and supports biopsy. [14]

Do not extrapolate the PLA2R exception to every patient with proteinuria. Biopsy remains appropriate when there is diagnostic uncertainty, including suspected systemic immune disease, paraprotein-related disease, FSGS, minimal change disease, or an atypical clinical course. Kidney manifestations of systemic vasculitis or systemic lupus erythematosus are explicit biopsy indications. [14]
- Biopsy unexplained progressive renal failure, including intrinsic acute kidney injury with glomerular urinary sediment. [14][15]
- Biopsy proteinuria greater than 1-2 g/24 hours with or without hypertension when the diagnosis is not otherwise established. [14]
- Biopsy proteinuria associated with dysmorphic erythrocytes or red blood cell casts, particularly with rising serum creatinine. [14]
- In diabetes, do not presume diabetic kidney disease when the clinical pattern is discordant; diabetic albuminuria with proven diabetic retinopathy is an exception cited for deferring biopsy. [14]

*Adult nephrotic syndrome biopsy decisions and immediate diagnostic implications. [13][14]*

| Clinical pattern | Action | What changes the next step |
| --- | --- | --- |
| New nephrotic syndrome without evident cause | Native kidney biopsy | Classifies the glomerular lesion and evaluates for unexpected diagnoses such as amyloidosis, fibrillary or immunotactoid glomerulopathy, or Fabry disease. [13][14] |
| New nephrotic syndrome with serum PLA2R-Ab detected | Consider primary membranous nephropathy diagnosis without biopsy | PLA2R-Ab detection is highly specific; retain biopsy when another diagnosis or pathologic information is needed. [14] |
| PLA2R-Ab negative nephrotic syndrome | Native kidney biopsy | Seronegativity does not establish membranous nephropathy and does not exclude alternative glomerular or infiltrative disease. [14] |
| Systemic lupus erythematosus or ANCA-associated vasculitis with suspected renal involvement | Native kidney biopsy | Determines renal pathology in a systemic disorder with suspected glomerular involvement. [14] |
| Diabetes with albuminuria and proven diabetic retinopathy | Individualize need for biopsy | This concordant pattern is cited as an exception to biopsy for proteinuria; discordant renal findings warrant reconsideration. [14] |

## Use age and glucocorticoid response to trigger biopsy

Initial empiric treatment is appropriate only for children with a typical steroid-sensitive presentation.

In children up to age 12 years with a typical idiopathic nephrotic presentation, begin glucocorticoid therapy rather than routinely performing biopsy at onset. Minimal change disease accounts for approximately 90% of idiopathic nephrotic syndrome in the first decade of life, and steroid response is more prognostic than initial histology in this group. [1][17]

Obtain kidney biopsy for pediatric nephrotic syndrome that fails to respond to initial corticosteroid therapy. Current pediatric guidance uses a 4- to 6-week confirmation period for children with only partial remission at week 4; further glucocorticoid therapy and renin-angiotensin system blockade are assessed during that interval. Steroid-resistant nephrotic syndrome is defined at 6 weeks, with or without a trial of three daily intravenous methylprednisolone doses, and biopsy plus genetic testing should follow. [16][19]

Perform biopsy at initial presentation in children older than 12 years with idiopathic nephrotic syndrome. In this age group, FSGS and other glomerular diseases, including membranous nephropathy and membranoproliferative glomerulopathy, are more prevalent than in younger children. [17]
- Reserve biopsy in younger children with presumed steroid-sensitive disease for corticosteroid nonresponse, frequent relapses, or atypical findings requiring an alternative diagnosis. [1]
- At suspected steroid resistance, obtain genetic testing alongside biopsy rather than escalating empiric immunosuppression without defining the disease category. [16][19]
- For children with complete glucocorticoid response who later relapse or become steroid dependent, use the KDIGO treatment algorithm to select a glucocorticoid-sparing agent; the choice among calcineurin inhibitor, oral cyclophosphamide, levamisole, mycophenolate mofetil, and rituximab depends on adverse effects, adherence, resources, and family preferences. [6][19]

### Findings that should override a biopsy-sparing pediatric approach

Do not assume minimal change disease when the presentation is outside the usual age-pattern or when the child has persistent corticosteroid nonresponse. The clinical purpose of tissue is to identify FSGS or another glomerulopathy and to guide the genetic and immunosuppressive pathway rather than continuing a steroid-sensitive nephrotic syndrome strategy. [16][17][19]

*Pediatric timing of biopsy in idiopathic nephrotic syndrome. [1][16][17][19]*

| Presentation | Biopsy timing | Decision rationale |
| --- | --- | --- |
| Typical idiopathic nephrotic syndrome, age 12 years or younger | Usually defer initially | Empiric corticosteroid therapy is standard because minimal change disease predominates in the first decade. [1][17] |
| Only partial remission after 4 weeks of glucocorticoids | Continue through the 4-6 week confirmation period while assessing renin-angiotensin system blockade | The confirmation period determines whether remission occurs before steroid-resistant nephrotic syndrome is assigned. [19] |
| No complete remission by 6 weeks | Biopsy and genetic testing | Defines steroid-resistant nephrotic syndrome in current guidance; an optional three-day intravenous methylprednisolone trial may precede final designation. [16][19] |
| New idiopathic nephrotic syndrome after age 12 years | Biopsy at presentation | FSGS and other glomerular diseases become more frequent with adolescent onset. [17] |
| Frequent relapses or other atypical features in a younger child | Consider biopsy | Biopsy is reserved for nonresponse, frequent relapses, or diagnostic uncertainty in pediatric minimal change disease pathways. [1] |

## Biopsy in pregnancy only when pathology will change near-term care

Antepartum biopsy is feasible but carries more bleeding risk than postpartum biopsy.

Consider kidney biopsy during pregnancy for de novo nephrotic syndrome, sudden deterioration in kidney function, or suspected glomerulonephritis when a pathologic diagnosis will change maternal treatment or pregnancy management. In contemporary biopsy cohorts, nephrotic syndrome without acute kidney injury has been a leading indication. [9][10]

When clinical urgency allows, defer biopsy until postpartum because pooled data found complications in 7% of antepartum biopsies versus 1% postpartum biopsies. Most reported complications were minor, including flank pain and macroscopic hematuria; significant complications clustered at 23-26 weeks' gestation. [9]

Do not let concern about biopsy obscure concurrent thrombotic risk assessment. Nephrotic syndrome with serum albumin below 25 g/L increases venous thromboembolism risk in pregnancy, and expert opinion supports thromboprophylaxis throughout pregnancy for severe proteinuria with albumin below 20-25 g/L, with individualized consideration at higher albumin concentrations when additional risk factors such as obesity or immobility are present. [9]
- Proceed antepartum when delay would prevent diagnosis or treatment of rapidly worsening kidney disease or active glomerulonephritis. [9]
- Prefer postpartum tissue diagnosis when maternal disease is clinically stable and pathology can safely wait. [9]
- Coordinate biopsy timing with anticoagulation planning because nephrotic syndrome and pregnancy both increase thrombotic risk. [9]

*Pregnancy-specific biopsy and thrombosis decisions in nephrotic syndrome. [9][10]*

| Scenario | Preferred action | Key tradeoff |
| --- | --- | --- |
| De novo nephrotic syndrome or suspected glomerulonephritis during pregnancy | Consider antepartum kidney biopsy if results will alter management | Antepartum pathology may establish a treatable diagnosis but carries higher complication risk than postpartum biopsy. [9][10] |
| Stable nephrotic syndrome without an urgent management-changing question | Defer biopsy until postpartum when feasible | Complications were 7% antepartum versus 1% postpartum in a pooled analysis. [9] |
| Severe proteinuria with albumin below 20-25 g/L | Consider thromboprophylaxis throughout pregnancy | Recommendation is expert opinion; balance bleeding risk and procedural plans. [9] |

## Confirm that biopsy will answer a management-changing question

Native kidney tissue should be pursued when it distinguishes diseases with materially different treatment or prognosis.

Before scheduling biopsy, define the clinical question in the requisition: primary membranous nephropathy versus another glomerular disease, immune-complex or pauci-immune glomerulonephritis, podocytopathy such as minimal change disease or FSGS, or an infiltrative or hereditary process. This framing determines the value of tissue when serology, systemic disease, or clinical trajectory does not establish the diagnosis. [14]

Treat biopsy as particularly high value in adult nephrotic syndrome with impaired kidney function, glomerular hematuria, or systemic features because these patterns broaden the differential beyond a primary podocytopathy. Progressive creatinine elevation with acanthocytes or red blood cell casts is a named indication for biopsy. [14]

A biopsy-sparing approach should remain narrow. PLA2R positivity can support a noninvasive diagnosis of primary membranous nephropathy, but it does not replace tissue evaluation for adults whose presentation suggests another renal process or whose management depends on histologic information. [14]
- Document current serum creatinine and urine sediment before biopsy; rising creatinine plus acanthocytes or red blood cell casts favors urgent tissue diagnosis. [14]
- Obtain PLA2R-Ab before biopsy in new adult nephrotic syndrome because a positive result may alter the need for initial histology. [14]
- Use biopsy in suspected systemic lupus erythematosus or ANCA-associated vasculitis with renal involvement rather than assigning nephrotic proteinuria to a primary glomerular disease without tissue. [14]

*Tests and clinical features that change the need or urgency for kidney biopsy. [14]*

| Finding | Interpretation | Biopsy consequence |
| --- | --- | --- |
| Serum PLA2R-Ab detected in new nephrotic syndrome | Supports primary membranous nephropathy | Biopsy may be deferred in selected patients. [14] |
| PLA2R-Ab absent | Does not establish membranous nephropathy and leaves a broad differential | Proceed with biopsy when nephrotic syndrome remains unexplained. [14] |
| Acanthocytes or red blood cell casts with progressive creatinine rise | Suggests glomerular inflammatory injury | Biopsy is indicated to define the lesion. [14] |
| Clinical or serologic evidence of SLE or ANCA vasculitis with kidney involvement | Systemic immune disease may be driving renal pathology | Biopsy is indicated. [14] |

## Common questions

### Can a positive PLA2R antibody test replace kidney biopsy in adult nephrotic syndrome?

In selected adults with new nephrotic syndrome, serum PLA2R-Ab detection is sufficiently specific for primary membranous nephropathy to avoid histologic confirmation. Biopsy remains appropriate when the presentation is atypical, another diagnosis is suspected, or pathologic information will alter management. [14]

### When is pediatric nephrotic syndrome considered steroid resistant for biopsy decisions?

Current pediatric guidance uses a 4-6 week confirmation period for partial remission at week 4 and defines steroid-resistant nephrotic syndrome at 6 weeks. Kidney biopsy and genetic testing should then be pursued; three daily intravenous methylprednisolone doses may be considered before final classification. [16][19]

## References
1. Minimal change disease - Symptoms, diagnosis and treatment | BMJ Best Practice US — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/940
2. Outcome of participants with nephrotic syndrome in combined ... — lupus.bmj.com — https://lupus.bmj.com/content/6/1/e000308.full.pdf
3. Percutaneous and surgical renal biopsies are - JAMA Network — jamanetwork.com — https://jamanetwork.com/journals/jama/articlepdf/340009/jama_205_4_011.pdf?resultClick=1
4. KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Glomerulonephritis - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0272638613009037
5. Canadian Society of Nephrology Commentary on the 2012 KDIGO Clinical Practice Guideline for Glomerulonephritis: Management of Glomerulonephritis in Adults - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0272638613015552
6. Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Nephrotic Syndrome in Children - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0085253824007968
7. KDOQI US Commentary on the KDIGO 2025 Clinical Practice Guideline for the Management of Nephrotic Syndrome in Children - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0272638625011473
8. Ten tips for the diagnosis and management of nephrotic syndrome — academic.oup.com — https://academic.oup.com/ckj/article/19/9/sfag268/8759701
9. Managing glomerular disease in pregnancy — academic.oup.com — https://academic.oup.com/ndt/article/32/suppl_1/i48/2930788
10. Kidney biopsy during pregnancy: indications, complications, results ... — academic.oup.com — https://academic.oup.com/ndt/advance-article/doi/10.1093/ndt/gfag108/8684969
11. Prophylactic anticoagulation in patients with nephrotic syndrome in ... — academic.oup.com — https://academic.oup.com/ckj/article/18/5/sfaf104/8113988
12. Nonvascular Renal Interventions: A Review and... : Seminars in ... — journals.lww.com — https://journals.lww.com/00010658-202410000-00007
13. KDIGO 2021 Clinical Practice Guideline for the Management of ... — www.kidney-international.org — https://www.kidney-international.org/article/S0085-2538(21)00562-7/fulltext
14. Renal Biopsy for Diagnosis in Kidney Disease: Indication, Technique, and Safety — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10573674
15. Kidney biopsy guidebook 2020 in Japan - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC7966701
16. Aligning Practice With Guidelines: A Canadian National Survey and Canadian Society of Nephrology Commentary on the 2025 KDIGO Pediatric Nephrotic Syndrome Recommendations - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC13219935
17. To biopsy or not to biopsy a teenager with idiopathic nephrotic syndrome? Biopsy first - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC11666677
18. KDIGO-2024-Lupus-Nephritis-Guideline.pdf — www.kidney-international.org — https://www.kidney-international.org/article/S0085-2538(23)00627-0/pdf
19. Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Nephrotic Syndrome in Children - Kidney International — www.kidney-international.org — https://www.kidney-international.org/article/S0085-2538(24)00796-8/fulltext
20. Renal Biopsy - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK470275
21. [PDF] Minimal change disease and focal segmental glomerulosclerosis in ... — www.nice.org.uk — https://www.nice.org.uk/guidance/es1/resources/minimal-change-disease-and-focal-segmental-glomerulosclerosis-in-adults-rituximab-pdf-32169639877
22. Minimal change disease and focal segmental glomerulosclerosis in ... — www.nice.org.uk — https://www.nice.org.uk/advice/es1/chapter/full-evidence-summary
23. [PDF] Chapter 10: Glomerular Disease in the Elderly — www.asn-online.org — https://www.asn-online.org/education/distancelearning/curricula/geriatrics/Chapter10.pdf
24. Nephrology - AAP Publications — publications.aap.org — https://publications.aap.org/book/chapter-pdf/1380714/aap_9781581109801-part03-ch32.pdf

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.